FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589460664> ?p ?o ?g. }

• W2589460664 endingPage "129" @default.
• W2589460664 startingPage "129" @default.
• W2589460664 abstract "129 Background: This study analyzed the risk of chemotherapy induced nausea and vomiting (N&V) [CINV] associated with palonosetron versus other 5-HT 3 receptor antagonists (5-HT 3 -RAs) initiation among patients with non-colon gastrointestinal cancers receiving chemotherapy (CT) in a hospital outpatient setting. Methods: Patients diagnosed with any non-colon gastrointestinal cancer initiating any CT and antiemetic prophylaxis with palonosetron (Group 1) or other 5-HT 3 -RAs (Group 2) for the first time (index date) between 4/1/2007-3/31/2009 were identified from the Premier Perspective database. Patients included were aged ≥ 18 years, with no evidence of N&V, CT, and antiemetic medication in the 6 month pre-index date period, and with at least 36 consecutive months of data. A negative binomial GLM regression analysis was done estimating the number of CINV events (identified through either ICD-9-CM codes for N&V and/or volume depletion or CINV-related rescue medications 1 day after CT administration) in the follow-up period (first of 8 CT cycles or 6 months post index date) between the 2 groups (after matching on CT and specific CT cycle). Results: Of 658 identified patients, 215 initiated on palonosetron (Group 1; 32.7%). Group 1 patients were significantly younger [61.7 (SD: 11.3) vs. 62.2 (12.1) years; p = 0.0073], a higher percent received highly emetogenic chemotherapy (27.4% vs. 19.4%; p < 0.0001), and comprised of less African Americans (7.0% vs. 13.3%). In the follow-up period, the unadjusted number of CINV events per patient per CT cycle for Group 1 patients was lower versus Group 2 patients, though statistically non-significant (4.7 vs. 5.2; p = 0.1714). However, after controlling for differences in demographic and clinical variables, the regression model predicted a statistically significant reduction (30.9%) in the total CINV events per patient per CT cycle in favor of Group 1 patients; p = 0.0086. Conclusions: In this analysis, patients with non-colon gastrointestinal cancers initiated on palonosetron were more likely to experience a significantly lower rate of CINV events per patient per CT cycle versus those initiated on other 5-HT3-RAs. [Table: see text]" @default.
• W2589460664 created "2017-03-03" @default.
• W2589460664 creator A5015721711 @default.
• W2589460664 creator A5019554240 @default.
• W2589460664 creator A5039543314 @default.
• W2589460664 creator A5041884618 @default.
• W2589460664 date "2011-02-01" @default.
• W2589460664 modified "2023-09-26" @default.
• W2589460664 title "Palonosetron versus other 5-HT3–receptor antagonists for chemotherapy-induced nausea and vomiting prevention in patients with noncolon gastrointestinal cancers." @default.
• W2589460664 doi "https://doi.org/10.1200/jco.2011.29.4_suppl.129" @default.
• W2589460664 hasPublicationYear "2011" @default.
• W2589460664 type Work @default.
• W2589460664 sameAs 2589460664 @default.
• W2589460664 citedByCount "0" @default.
• W2589460664 crossrefType "journal-article" @default.
• W2589460664 hasAuthorship W2589460664A5015721711 @default.
• W2589460664 hasAuthorship W2589460664A5019554240 @default.
• W2589460664 hasAuthorship W2589460664A5039543314 @default.
• W2589460664 hasAuthorship W2589460664A5041884618 @default.
• W2589460664 hasConcept C121608353 @default.
• W2589460664 hasConcept C126322002 @default.
• W2589460664 hasConcept C2776694085 @default.
• W2589460664 hasConcept C2776712918 @default.
• W2589460664 hasConcept C2779924295 @default.
• W2589460664 hasConcept C2780580376 @default.
• W2589460664 hasConcept C2780852908 @default.
• W2589460664 hasConcept C2780884295 @default.
• W2589460664 hasConcept C42219234 @default.
• W2589460664 hasConcept C526805850 @default.
• W2589460664 hasConcept C71924100 @default.
• W2589460664 hasConcept C90924648 @default.
• W2589460664 hasConceptScore W2589460664C121608353 @default.
• W2589460664 hasConceptScore W2589460664C126322002 @default.
• W2589460664 hasConceptScore W2589460664C2776694085 @default.
• W2589460664 hasConceptScore W2589460664C2776712918 @default.
• W2589460664 hasConceptScore W2589460664C2779924295 @default.
• W2589460664 hasConceptScore W2589460664C2780580376 @default.
• W2589460664 hasConceptScore W2589460664C2780852908 @default.
• W2589460664 hasConceptScore W2589460664C2780884295 @default.
• W2589460664 hasConceptScore W2589460664C42219234 @default.
• W2589460664 hasConceptScore W2589460664C526805850 @default.
• W2589460664 hasConceptScore W2589460664C71924100 @default.
• W2589460664 hasConceptScore W2589460664C90924648 @default.
• W2589460664 hasIssue "4_suppl" @default.
• W2589460664 hasLocation W25894606641 @default.
• W2589460664 hasOpenAccess W2589460664 @default.
• W2589460664 hasPrimaryLocation W25894606641 @default.
• W2589460664 hasRelatedWork W1480067006 @default.
• W2589460664 hasRelatedWork W2003876327 @default.
• W2589460664 hasRelatedWork W2020302560 @default.
• W2589460664 hasRelatedWork W2032692004 @default.
• W2589460664 hasRelatedWork W2037186270 @default.
• W2589460664 hasRelatedWork W2052445101 @default.
• W2589460664 hasRelatedWork W2376134526 @default.
• W2589460664 hasRelatedWork W2384787271 @default.
• W2589460664 hasRelatedWork W2897258609 @default.
• W2589460664 hasRelatedWork W4206589757 @default.
• W2589460664 hasVolume "29" @default.
• W2589460664 isParatext "false" @default.
• W2589460664 isRetracted "false" @default.
• W2589460664 magId "2589460664" @default.
• W2589460664 workType "article" @default.